Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+breast cancer (TRIO-US B07)

被引：13
|
作者：
Hurvitz, S. A.
Miller, J. M.
Dichmann, R.
Perez, A. T.
Patel, R.
Zehngebot, L. M.
Allen, H.
Bosserman, L. D.
DiCarlo, B. A.
Kennedy, A.
Giuliano, A.
Calfa, C. J.
Molthrop, D. C.
Mani, A.
Dering, J.
Wang, H-J
Adams, B.
Martinez, D.
Chen, W.
Zoeller, J.
Brugge, J. S.
Slamon, D. J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Olive View Med Ctr, Sylmar, CA USA
[3] Cent Coast Med Oncol, Santa Maria, CA USA
[4] Mem Canc Inst, Hollywood, FL USA
[5] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[6] Hematol Oncol Consultants PA, Orlando, FL USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] Wilshire Oncol Med Grp, Rancho Cucamonga, CA USA
[9] Coastal Integrat Canc Care, San Luis Obispo, CA USA
[10] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[11] Harvard Univ, Sch Med, Boston, MA USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-S1-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H plus Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+Breast Cancer
    Callahan, R. D.
    Patel, R.
    Chan, D.
    Allison, M. A.
    DiCarlo, B.
    Bosserman, L. D.
    Kennedy, A.
    Zehngebot, L. M.
    Miller, J.
    Giuliano, A. E.
    Spivack, B.
    Lin, L-s
    Slamon, D. J.
    Hurvitz, S. A.
    CANCER RESEARCH, 2010, 70
  • [2] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
    Hurvitz, Sara A.
    Caswell-Jin, Jennifer L.
    McNamara, Katherine L.
    Zoeller, Jason J.
    Bean, Gregory R.
    Dichmann, Robert
    Perez, Alejandra
    Patel, Ravindranath
    Zehngebot, Lee
    Allen, Heather
    Bosserman, Linda
    DiCarlo, Brian
    Kennedy, April
    Giuliano, Armando
    Calfa, Carmen
    Molthrop, David
    Mani, Aruna
    Chen, Hsiao-Wang
    Dering, Judy
    Adams, Brad
    Kotler, Eran
    Press, Michael F.
    Brugge, Joan S.
    Curtis, Christina
    Slamon, Dennis J.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [3] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
    Sara A. Hurvitz
    Jennifer L. Caswell-Jin
    Katherine L. McNamara
    Jason J. Zoeller
    Gregory R. Bean
    Robert Dichmann
    Alejandra Perez
    Ravindranath Patel
    Lee Zehngebot
    Heather Allen
    Linda Bosserman
    Brian DiCarlo
    April Kennedy
    Armando Giuliano
    Carmen Calfa
    David Molthrop
    Aruna Mani
    Hsiao-Wang Chen
    Judy Dering
    Brad Adams
    Eran Kotler
    Michael F. Press
    Joan S. Brugge
    Christina Curtis
    Dennis J. Slamon
    Nature Communications, 11
  • [4] Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.
    Guarneri, V.
    Frassoldati, A.
    Ficarra, G.
    Maiorana, A.
    Bettelli, S.
    Bottini, A.
    Cagossi, K.
    Bisagni, G.
    Ravaioli, A.
    Amadori, D.
    Musolino, A.
    Cavanna, L.
    Orlando, L.
    Giardina, G.
    Piacentini, F.
    Bagnalasta, M.
    Conte, P.
    CANCER RESEARCH, 2011, 71
  • [5] TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer
    Chang, J. C. N.
    Mayer, I. A.
    Forero-Torres, A.
    Nanda, R.
    Goetz, M. P.
    Rodriguez, A. A.
    Pavlick, A. C.
    Wang, T.
    Hilsenbeck, S. G.
    Gutierrez, C.
    Schiff, R.
    Osborne, C. K.
    Rimawi, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US B-09)
    Hurvitz, S. A.
    Martinez, D. A.
    Singh, R.
    Taguchi, J.
    Chan, D.
    Dichmann, R.
    Castrellon, A.
    Barstis, J.
    Hu, E.
    Berkowitz, J.
    Mani, A.
    DiCarlo, B.
    Smalberg, I.
    Hobbs, E.
    Slamon, D. J.
    CANCER RESEARCH, 2017, 77
  • [7] A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
    Veeraraghavan, J.
    De Angelis, C.
    Mao, R.
    Wang, T.
    Herrera, S.
    Pavlick, A. C.
    Contreras, A.
    Nuciforo, P.
    Mayer, I. A.
    Forero, A.
    Nanda, R.
    Goetz, M. P.
    Chang, J. C.
    Wolff, A. C.
    Krop, I. E.
    Fuqua, S. A. W.
    Prat, A.
    Hilsenbeck, S. G.
    Weigelt, B.
    Reis-Filho, J. S.
    Gutierrez, C.
    Osborne, C. K.
    Rimawi, M. F.
    Schiff, R.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 927 - 933
  • [8] Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment
    Sim, S. H.
    Park, I. H.
    Jung, K. H.
    Kim, S-B
    Ahn, J-H
    Lee, K-H
    Im, S-A
    Im, Y-H
    Park, Y. H.
    Sohn, J. H.
    Kim, Y. J.
    Lee, S.
    Kim, H-J
    Chae, Y. S.
    Park, K-H
    Nam, B-H
    Lee, K. S.
    Ro, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy
    Blackwell, K. L.
    Burstein, H. J.
    Sledge, G. W.
    Stein, S.
    Ellis, C.
    Casey, M.
    Baselga, J.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2009, 69 (24) : 499S - 499S
  • [10] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345